| First Author | Song Z | Year | 2022 |
| Journal | Front Immunol | Volume | 13 |
| Pages | 762390 | PubMed ID | 35359977 |
| Mgi Jnum | J:322794 | Mgi Id | MGI:7258951 |
| Doi | 10.3389/fimmu.2022.762390 | Citation | Song Z, et al. (2022) B Cell IL-4 Drives Th2 Responses In Vivo, Ameliorates Allograft Rejection, and Promotes Allergic Airway Disease. Front Immunol 13:762390 |
| abstractText | B cells can be polarized to express various cytokines. The roles of IFNgamma and IL-10, expressed respectively by B effector 1 (Be1) and Bregs, have been established in pathogen clearance, tumor growth, autoimmunity and allograft rejection. However, the in vivo role of B cell IL-4, produced by Be2 cells, remains to be established. We developed B-IL-4/13 iKO mice carrying a tamoxifen-inducible B cell-specific deletion of IL-4 and IL-13. After alloimmunization, B-IL-4/13 iKO mice exhibited decreased IL-4(+) Th2 cells and IL-10(+) Bregs without impact on Th1, Tregs, or CD8 T cell responses. B-IL-4/13 iKO mice rejected islet allografts more rapidly, even when treated with tolerogenic anti-TIM-1 mAb. In ovalbumin-induced allergic airway disease (AAD), B-IL-4/13 iKO mice had reduced inflammatory cells in BAL, and preserved lung histology with markedly decreased infiltration by IL-4(+) and IL-5(+) CD4(+) T cells. Hence, B cell IL-4 is a major driver of Th2 responses in vivo which promotes allograft survival, and conversely, worsens AAD. |
